

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Mareke Hartig, et al.) Art Unit: 1615
U.S. Appln. No. : 10/718,404) Examiner: Carlos A. Azpuru
Confirmation No. : 9739
U.S. Filing Date : 11/20/2003
Title of Invention : Tiotropium Containing Powder Formulation For Inhalation
Attny. Docket No.: 01-1425

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO FINAL OFFICE ACTION

Sir:

This Reply is being filed in response to the April 23, 2009 Office Action issued in the above-identified application. In that Office Action, a three-month shortened statutory period was set for response. Applicant hereby petitions for the necessary three-month extension of time under 37 C.F.R. § 1.136 to respond to that action and note that the fee required under 37 C.F.R. § 1.17(a) in connection with this extension of time will be paid during electronic filing via the Revenue Accounting and Management System. Applicant also petitions for a Request for Continued Examination (RCE) and the fee required under 37 C.F.R. § 1.17(e) will be paid during electronic filing. Furthermore, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Reply or RCE, authorization to charge such fees to Deposit Account No. 02-2955 will be provided during electronic filing.

A Listing of Claims begins on page 2 of this paper.

Remarks begin on page 3 of this paper.